Benefits, mechanisms, and risks of intermittent fasting in metabolic syndrome and type 2 diabetes

2022 ◽  
Author(s):  
Lisandra Joaquim ◽  
Ana Faria ◽  
Helena Loureiro ◽  
Paulo Matafome
Keyword(s):  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Intermittent Fasting

scholarly journals Hepatic-Metabolite-Based Intermittent Fasting Enables a Sustained Reduction in Insulin Resistance in Type 2 Diabetes and Metabolic Syndrome

2021 ◽  
Author(s):  
Markus Rohner ◽  
Robert Heiz ◽  
Simon Feldhaus ◽  
Stefan R. Bornstein
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Intermittent Fasting ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

AbstractInsulin resistance is the hallmark of Type 2 Diabetes and is still an unmet medical need. Insulin resistance lies at the crossroads of non-alcoholic fatty liver disease, obesity, weight loss and exercise resistance, heart disease, stroke, depression, and brain health. Insulin resistance is purely nutrition related, with a typical molecular disease food intake pattern. The insulin resistant state is accessible by TyG as the appropriate surrogate marker, which is found to lead the personalized molecular hepatic nutrition system for highly efficient insulin resistance remission. Treating insulin resistance with a molecular nutrition-centered approach shifts the treatment paradigm of Type 2 Diabetes from management to cure. This allows remission within five months, with a high efficiency rate of 85%. With molecular intermittent fasting a very efficient treatment for prediabetes and metabolic syndrome is possible, improving the non-alcoholic fatty liver disease (NAFL) state and enabling the body to lose weight in a sustainable manner.

Sign in / Sign up

Export Citation Format

Share Document